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A B S T R A C T
Mutations in the GAP activity toward RAGs 1 (GATOR1) complex genes (DEPDC5, NPRL2 and NPRL3) have been
associated with focal epilepsy and focal cortical dysplasia (FCD). GATOR1 functions as an inhibitor of the
mTORC1 signalling pathway, indicating that the downstream effects of mTORC1 deregulation underpin the
disease. However, the vast majority of putative disease-causing variants have not been functionally assessed for
mTORC1 repression activity. Here, we develop a novel in vitro functional assay that enables rapid assessment of
GATOR1-gene variants. Surprisingly, of the 17 variants tested, we show that only six showed significantly im-
paired mTORC1 inhibition. To further investigate variant function in vivo, we generated a conditional Depdc5
mouse which modelled a ‘second-hit’ mechanism of disease. Generation of Depdc5 null ‘clones’ in the embryonic
brain resulted in mTORC1 hyperactivity and modelled epilepsy and FCD symptoms including large dysmorphic
neurons, defective migration and lower seizure thresholds. Using this model, we validated DEPDC5 variant
F164del to be loss-of-function. We also show that Q542P is not functionally compromised in vivo, consistent with
our in vitro findings. Overall, our data show that mTORC1 deregulation is the central pathological mechanism for
GATOR1 variants and also indicates that a significant proportion of putative disease variants are pathologically
inert, highlighting the importance of GATOR1 variant functional assessment.
1. Introduction
Focal epilepsy is a disease characterised by recurring seizures that
occur in a localized region of the brain and can be caused by a range of
environmental and genetic factors (Boillot and Baulac, 2016; Guo et al.,
2013; Thomas and Berkovic, 2014). Recently, genes encoding the
subunits comprising the GATOR1 complex, NPRL2, NPRL3 and
DEPDC5, were shown to be mutated in families with focal epilepsy
(Baldassari et al., 2018; Dibbens et al., 2013; Ricos et al., 2016). In
these patients, seizures occur at variable foci – indeed, affected in-
dividuals who carry the same germline mutation can have seizures
originating from different cortical regions (Baldassari et al., 2018;
Dibbens et al., 2013; Ricos et al., 2016). The severity of the disease
symptoms also varies greatly, with cases of associated autism, cognitive
delays and reports of Sudden Unexpected Death related to Epilepsy
(SUDEP) (Bagnall et al., 2017; Nascimento et al., 2015; Weckhuysen
et al., 2016). Some patients have focal cortical dysplasia (FCD) (type II),
which involves defects in cortical lamination and the presence of large,
dysmorphic neurons (Cen et al., 2017; Kabat and Król, 2012; Scerri
et al., 2015; Weckhuysen et al., 2016).
Although GATOR1 mutations display autosomal dominant in-
heritance, there is also incomplete penetrance (Dibbens et al., 2013;
Ricos et al., 2016). A somatic ‘second-hit’ mutation mechanism for
GATOR1 epilepsies may underpin these diseases (D'Gama et al., 2017;
Hu et al., 2018; Ribierre et al., 2018). It has been proposed that a
second somatic mutation occurs in a neural progenitor cell of germline
heterozygous patients, thereby generating a population of compound
heterozygous cells that lacks GATOR1 function, from which seizures
may arise. This is supported by two recent cases of DEPDC5 epilepsy, in
which somatic mutations have been identified in brain tissue isolated
https://doi.org/10.1016/j.nbd.2019.104640
Received 6 May 2019; Received in revised form 7 October 2019; Accepted 13 October 2019
⁎ Corresponding author at: School of Medicine, University of Adelaide, Adelaide, SA 5005, Australia
E-mail addresses: ruby.dawson@adelaide.edu.au (R.E. Dawson), alvaro.nietoguil@adelaide.edu.au (A.F. Nieto Guil),
louise.robertson@adelaide.edu.au (L.J. Robertson), sandra.piltz@adelaide.edu.au (S.G. Piltz), hugh0285@flinders.edu.au (J.N. Hughes),
paul.thomas@adelaide.edu.au (P.Q. Thomas).
Neurobiology of Disease 134 (2020) 104640
Available online 19 October 2019
0969-9961/ © 2019 Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/BY-NC-ND/4.0/).
T
from patients with germline heterozygous mutations (Baulac et al.,
2015; Ribierre et al., 2018).
Previous in vitro studies have shown that GATOR1 functions to ne-
gatively regulate signalling of the mechanistic target of rapamycin
complex 1 (mTORC1) pathway, with knockdown cell lines being in-
sensitive to amino acid starvation, (Bar-Peled et al., 2013; Iffland et al.,
2018). More recently, rodent models with global and focal Depdc5 loss-
of-function have also shown the importance of Depdc5 in regulating
mTORC1 in vivo (Hu et al., 2018; Hughes et al., 2017; Ribierre et al.,
2018; Yuskaitis et al., 2017). The mTORC1 pathway is involved in
regulating many important cellular processes such as cell growth,
protein synthesis and autophagy, and its deregulation has been linked
with diseases including cancer and epilepsy, through the mutation of
other repressors of the pathway (D'Gama et al., 2017; Lipton and Sahin,
2014; Meng et al., 2013). Indeed, germline and somatic mutations have
been found in other mTORC1 pathway genes such as TSC1/2, AKT,
PIK3CA and mTOR itself, in cases of hemimegaloencephaly and FCD-
related epilepsy (D'Gama et al., 2017; Møller et al., 2016; Park et al.,
2018). As an inhibitor of mTORC1, mutations in GATOR1 are predicted
to cause epilepsy through mTORC1 hyperactivity, although the me-
chanism by which mTORC1 hyperactivity causes epilepsy and asso-
ciated pathologies is not known (Baulac, 2016).
Since their implication in epilepsy, a large number of GATOR1 gene
variants have been identified (Baldassari et al., 2018). However, due to
the complex mechanism of the disease, the causative status of many
GATOR1 variants is unclear, confounding definitive diagnosis, genetic
counselling, treatment strategies and prediction of disease outcomes.
This is especially true for in-frame or missense mutations where the
functional impact is often difficult to predict. Although bioinformatic
and in silico predictions have provided clues for the functional outcome
of these variants, the vast majority of GATOR1 mutations have not been
functionally assessed (Baldassari et al., 2018; Ricos et al., 2016; van
Kranenburg et al., 2015).
Here, we describe a novel in vitro functional assay to assess the
impact of 17 putative pathogenic GATOR1 variants on regulation of the
mTORC1 pathway. We also describe a unique conditional ‘second-hit’
Depdc5 mouse model and use this system to perform further functional
assessment of selected DEPDC5 variants in vivo. We show that a subset
of GATOR1 variants are functionally compromised, indicating that
mTORC1 deregulation is central to the pathological mechanism un-
derpinning GATOR1-related focal epilepsy. Remarkably, we also show
that vast majority of GATOR1 missense variants are not functionally
compromised, underlining the importance of functional assessment in
ascribing pathogenic status.
2. Results
2.1. Generation of GATOR1 gene null cell lines
We initially generated HEK293T cell lines lacking functional NPRL2,
NPRL3 or DEPDC5 using a CRISPR/CAS9 exon deletion frameshift
strategy (Supplemental Fig. 1A-C). To assess the impact of GATOR1
loss-of-function on mTORC1 signalling, null cells were cultured in the
absence of serum for 1 h. mTORC1 activity was then assessed via
phosphorylation of S6 protein at Ser240/244 (p-S6), a well-validated
downstream marker of mTORC1 activity (Bar-Peled et al., 2013;
Hughes et al., 2017; Ribierre et al., 2018). As expected, mTORC1 ac-
tivity was reduced in starved control cells compared to complete media
(Figs. 1A, 2A, 3A). However, consistent with previous reports (Bar-
Peled et al., 2013), null cells were unable to downregulate mTORC1 in
starvation conditions, as indicated by the persistence of high p-S6 le-
vels, comparable to those observed in complete media. Addition of the
mTORC1 inhibitor rapamycin decreased mTORC1 activity in null cells
(Figs. 1A, 2A, 3A). Identical results were obtained using independent
GATOR1 null cell lines generated with different gRNAs (Supplemental
Fig. 2A) confirming that the starvation insensitivity phenotype is due to
mutation of NPRL2, NPRL3 or DEPDC5.
2.2. Identification of functional mutants in GATOR1 complex genes
To assess the functional impact of reported pathogenic GATOR1
variants, we sought to develop a quantitative mTORC1 rescue assay. As
a positive control, null cells were transiently transfected with a rescue
expression construct encoding the corresponding WT GATOR1 gene and
a GFP reporter. After 1-hour serum starvation, cells were stained for p-
S6. In each null cell line, p-S6 was markedly reduced by expression of
the rescue construct but not by GFP alone (Supplemental Figs. 3–5). To
enable higher-throughput quantitative analysis, flow cytometry was
performed on the transfected null cells in complete media and starva-
tion conditions (Figs. 1C-D, 2C-D, 3C-D). In all GATOR1 null cell lines,
expression of the rescue construct significantly increased in the pro-
portion of cells with low p-S6 expression compared with GFP-only
control cells (Ρ≤ 0.0001, two-way ANOVA) (Figs. 1J, 2J and 3K).
Next, we used this rescue assay to assess the function of putative
disease-causing variants in NPRL2 (5), NPRL3 (5) and DEPDC5 (7)
(Figs. 1B, 2B, 3B, Supplemental Fig. 6A, Table 1). The NPRL2 missense
variant L105P failed to rescue mTORC1 hyperactivity indicating com-
plete loss-of-function (Fig. 1F, J). Steady-state expression of this variant
was comparable to WT NPRL2, indicating that loss-of-function was not
due to reduced protein levels (Fig. 1K). The two remaining NPRL2
missense variants, T110S and D214H, had comparable function to WT
NPRL2 (Fig. 1G-H, J). Interestingly, variant R34*, although truncated at
34 amino acids, was also not significantly different to WT NPRL2 with
~22% of cells inhibiting mTORC1 in starved conditions above back-
ground levels (Fig. 1E, J). This is likely due to a second isoform pro-
duced from an internal initiation codon, which was detected by western
blot analysis and may be functional at higher than endogenous levels of
expression (Fig. 1K) (Hesson et al., 2007). Surprisingly, nonsense mu-
tant R295* was also able to rescue the mTORC1 hyperactivity, despite a
drastic reduction in protein size (Fig. 1I-K).
Both NPRL3 missense mutations (R92Q, E249K) were functionally
intact (Fig. 2E-F, J). In contrast, the remaining three variants, all of
which were premature termination mutations (S279F fs*52, W319P
fs*13, S460P fs*20), had significantly reduced activity compared to
NPRL3 WT (Fig. 2G-I, J). It should be noted that variant S460P fs*20
retained some function as seen by the slight but significant increase in
cells with low mTORC1 in starved conditions, when compared with
complete media conditions (Ρ≤ 0.05, unpaired t-test) (Fig. 2J). Wes-
tern blot analysis of mutant proteins revealed similar expression levels
to WT and the expected size reduction of the truncation mutants
(Fig. 2K).
From the seven DEPDC5 variants tested, one indel mutation
(F164del) and one nonsense mutation (D1556*) had significantly re-
duced function (Fig. 3E, J, K). The former is an in-frame phenylalanine
deletion which produces near full-length protein (Fig. 3L). Notably, we
did see a slight, but not significant (p= .068, unpaired t-test) increase
in F164del-expressing cells which repressed mTORC1 in starved con-
ditions when compared to complete media, suggesting that some
function may be retained in this mutant (Fig. 3E,K). Flow cytometry
indicated that this mutant has increased activity at high levels of ex-
pression (Fig. 3E). D1556* is a de novo nonsense mutation close to the
stop codon, only truncating 39 amino acids of the full length protein.
The loss-of-function of this variant is potentially due to protein in-
stability, as seen by low protein expression on western blot (Fig. 3I, K-
L). The four other DEPDC5 variants, all of which encoded missense
mutations, did not have significantly altered function (Fig. 3F–H, K,
Supplemental Fig. 6A–D).
These results were replicated and validated with independent
NPRL2, NPRL3 and DEPDC5 null cell lines, showing there were no
confounding effects from potential off-target mutations (Supplemental
Fig. 2B–D). Overall, the majority of patient variants tested in this assay
did not exhibit significant loss-of-function. Indeed, of the 17 variants
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Fig. 1. Functional testing of NPRL2 variants. (A) mTORC1 activity is unable to be downregulated in serum starved NPRL2 null cells compared to empty vector
controls, as shown by persistent p-S6 staining on western blot. Addition of rapamycin rescues the null cell ability to repress p-S6. (B) Schematic representation of
NPRL2 with patient variants. The variant in red was shown to be a loss-of-function mutant. (C–I) Representative plots of flow cytometry analysis performed on null
cells transfected with variant constructs containing GFP in complete media and starved conditions, and staining for p-S6. Mean percentage of cells in bottom right
quadrant is indicated inside plots. (J) Box and whisker plot of quantification of transfected cells with low mTORC1 activity determined by flow cytometry analysis,
indicating variant functional ability to repress mTORC1 in starved conditions (****= p < .0001, ***= p < .001, Two-way ANOVA with Dunnett's multiple
comparisons tests, n=5–7). (K) Western blot showing expression of NPRL2 variants and GFP marker in lysates of transfected NPRL2 null cells. (For interpretation of
the references to colour in this figure legend, the reader is referred to the web version of this article.)
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Fig. 2. Functional testing of NPRL3 variants. (A) mTORC1 activity is unable to be downregulated in serum starved NPRL3 null cells compared to empty vector
controls, as shown by persistent p-S6 staining on western blot. Addition of rapamycin rescues the null cell ability to repress p-S6. (B) Schematic representation of
NPRL3 with patient variants. Variants in red were shown to be loss-of-function mutants. (C–I) Representative plots of flow cytometry analysis performed on null cells
transfected with variant constructs containing GFP in complete media and starved conditions, and staining for p-S6. Mean percentage of cells in bottom right
quadrant is indicated inside plots. (J) Box and whisker plot of quantification of transfected cells with low mTORC1 activity determined by flow cytometry analysis,
indicating variant functional ability to repress mTORC1 in starved conditions (****= p < .0001, ***= p < .001, *= p < .05, Two-way ANOVA with Dunnett's
multiple comparisons tests, n=5–9). (K) Western blot showing expression of NPRL3 variants and GFP marker in lysates of transfected NPRL3 null cells. (For
interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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tested, loss-of-function was only observed in one missense NPRL2 var-
iant, three nonsense NPRL3 variants, one indel DEPDC5 variant and one
nonsense DEPDC5 variant. These results underline the importance of
functional assessment of GATOR1 variants that are genetically im-
plicated in disease causation.
2.3. A conditional model of a second-hit mutation of Depdc5 in the
developing mouse brain has hyperactive mTORC1 and shows epileptic and
FCD phenotypes
Having established defective mTORC1 regulation for some GATOR1
variants in vitro, we next investigated the role of mTORC1 in GATOR1-
related epilepsy in vivo. To accurately model the ‘second-hit’ me-
chanism of disease, we first generated a Depdc5 ‘floxed’ conditional
mouse model using CRISPR/CAS9. The floxed allele includes loxP sites
flanking exon 3 of Depdc5 and the recombined product results in a
frameshift (c.59_146del p.20Asp fs*25) (Supplemental Fig. 7A,B). We
then generated Depdc5flox/null embryos using a previously generated
constitutive null allele for Depdc5 which has the same exon deleted
(Hughes et al., 2017). For simplicity, Depdc5flox/null and Depdc5flox/WT
mice will be referred to as flox/null and flox/WT hereafter. Finally, we
used in utero electroporation to co-deliver plasmids encoding Cre re-
combinase (pCIG-Cre) and GFP (pCAG-GFP) to the brains of developing
flox/null and flox/WT littermate embryos (14.5dpc). This generated
GFP-positive null cell ‘clones’ within a heterozygous background
thereby mimicking a second, somatic mutation in Depdc5 during em-
bryonic CNS development (Fig. 4A, Supplemental Fig. 7C). We con-
firmed Cre recombinase expression in GFP-positive neurons with an
anti-CRE antibody and found very high levels of co-localisation
(Fig. 4B). Additionally, to confirm recombination of the floxed allele in
the presence of CRE, we amplified transcripts from GFP-sorted neurons
from floxed embryos. Efficient generation of the null deletion allele was
observed (Fig. 4C,D).
Given the elevated mTORC1 activity in GATOR1 null cell lines, we
initially assessed the impact of clonal DEPDC5 deletion by assessing p-
S6 levels. In adult mouse brains (P42) co-electroporated with Cre/GFP
plasmids at 14.5dpc, we found that GFP-positive neurons in flox/null
mice had a ~2-fold increase in p-S6 levels compared to flox/WT con-
trols (Fig. 4E, F). Interestingly, we also observed elevated p-S6 ex-
pression in neighbouring GFP-negative neurons, indicating a possible
cell non-autonomous effect. As mTORC1 controls cell growth, we also
compared the soma size of GFP-positive flox/null and flox/WT neurons.
We found that null neuron soma were on average 1.7 fold larger, and
observed a range of sizes up to 3.5 fold larger than controls (Fig. 4E′, G,
H). Some of these enlarged null neurons also exhibited an abnormal
rounded morphology, similar to that seen in giant cells seen in tuberous
sclerosis complex (TSC) patient tubers, or balloon cells seen in FCD type
IIb (Fig. 4E′, H, I). Typically, balloon cells express immature markers
such as Nestin, however, we did not see Nestin-positive neurons (data
not shown) (Blümcke et al., 2011; Oh et al., 2008). We saw no differ-
ence in staining or localisation of SMI32 in flox/null tissue (data not
shown). Rather, large dysmorphic neurons stained for NeuN, a mature
neuronal marker, which may be more representative of FCD type IIa
rather than type IIb (Fig. 4H) (Hu et al., 2018; Kabat and Król, 2012).
The stellate morphology of Depdc5-null neurons indicated abnormal
dendritic growth and arrangement. We therefore performed neuronal
reconstruction analysis, which revealed that Depdc5-null neurons had a
significant increase in the number of dendritic branch points, re-
presenting increased complexity and growth of flox/null dendrites
compared to controls (Fig. 4I,J).
As cortical lamination is a feature of FCD type II, we measured the
distribution of GFP-positive null neurons in layer II-III and layer IV. The
majority of cells electroporated at 14.5dpc should migrate to layers II-
III (Kwan et al., 2012; Ling et al., 2016; Ribierre et al., 2018). Indeed,
we found over 80% of electroporated neurons in flox/WT cells at P42
were located in II/III, with the remaining in layer IV. However, in flox/
null brains, only 39% of GFP-positive neurons were found in layers II/
III while the remaining 61% neurons were in layer IV, indicating a
migration defect across cortical layers II-IV (Fig. 5A–C). We did not
observe ectopic neurons in any deeper cortical layers.
Given the epileptic phenotype of DEPDC5 patients, we anticipated
flox/null electroporated mice may be prone to seizures. As no overt
spontaneous seizures were observed in flox/null or flox/WT mice
during routine handling, we challenged the mice to a chemically in-
duced seizure test using Pentylenetetrazol (PTZ). Administration of PTZ
did not induce full generalised tonic-clonic (GTC) seizures in any flox/
WT control mice within a 1-hour period, but was sufficient to induce
GTC seizures in flox/null mice in 26 mins on average, indicating a
significantly lowered seizure threshold (Fig. 5D).
Together, these data show that focal loss of Depdc5 in mice causes
hyperactivation of mTORC1 signalling and phenocopies GATOR1 de-
ficiency in humans.
3. In vivo functional analysis of DEPDC5 variants F164del and
Q542P
Finally, we sought to investigate the function of two disease-asso-
ciated DEPDC5 variants in the context of the developing mammalian
brain using the conditional ‘second-hit’ mouse model. We selected the
relatively common F164del DEPDC5 variant (confirmed in vitro to be
loss-of-function) and Q542P (determined to be functional in vitro) to
perform in vivo rescue experiments (Baldassari et al., 2018; Ricos et al.,
2016). WT DEPDC5, F164del or Q542P expression constructs were co-
electroporated with Cre/GFP plasmids at 14.5dpc (Fig. 4A). To confirm
the successful electroporation and expression of the mutant, GFP-posi-
tive tissue was microdissected from P0 brains. RT-PCR amplification of
cDNA transcript showed that the specific Flag-DEPDC5 sequence was
present only in the electroporated tissue for WT, F164del and Q542P
constructs (Fig. 6A).
We first set out to determine if expression of F164del or Q542P in
Depdc5-null neurons would rescue the mTORC1 hyperactivity in
Depdc5-null neurons. In P15 mouse brains co-electroporated with WT
DEPDC5 construct, GFP-neurons had p-S6 levels comparable to flox/WT
controls, indicating a successful rescue of hyperactive mTORC1 of null
neurons (Fig. 6B, C). Expression of Q542P also restored p-S6 levels to
those of flox/WT controls consistent with our in vitro experiments. In
contrast, p-S6 staining was ~2.6 fold higher in neurons electroporated
with F164del compared with WT DEPDC5 rescue and flox/WT controls
(Fig. 6B, C). While the p-S6 levels of F164del neurons were significantly
higher than these controls, it is important to note that there remained a
slight but significant difference between null neurons and F164del
neurons, likely due to a low level of residual F164del function at high
Fig. 3. Functional testing ofDEPDC5 variants. (A) mTORC1 activity is unable to be downregulated in serum starved DEPDC5 null cells compared to empty vector
controls, as shown by persistent p-S6 staining on western blot. Addition of rapamycin rescues the null cell ability to repress p-S6. (B) Schematic representation of
DEPDC5 with patient variants. Variants in red were shown to be loss-of-function mutants. (C–J) Representative plots of flow cytometry analysis performed on null
cells transfected with variant constructs containing GFP in complete media and starved conditions, staining for p-S6. Mean percentage of cells in bottom right
quadrant is indicated inside plots. (K) Box and whisker plot of quantification of transfected cells with low mTORC1 activity determined by flow cytometry analysis,
indicating variant functional ability to repress mTORC1 in starved conditions. (****= p < .0001, ***= p < .001, Two-way ANOVA with Dunnett's multiple
comparisons tests, n=4–6. (L) Western blot showing expression of DEPDC5 variants and GFP marker in lysates of transfected DEPDC5 null cells. (For interpretation
of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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levels of expression.
We then measured soma size to determine whether this mTORC1
phenotype was rescued by Q542P or F164del expression. We compared
soma sizes by layer and found that soma of layer II-III and layer IV
Depdc5-null neurons were both larger than control neurons (Fig. 6D–F).
We noticed that the fold change in size was not as drastic as those
measured at P42 which suggests that null neurons may continue to
grow larger over development and throughout adulthood, making the
phenotype progressively more severe. The co-electroporation of WT
DEPDC5 was sufficient to return the soma size to that of flox/WT
control in both layers II-III and layer IV, confirming that the difference
in soma size is a direct result of loss of DEPDC5 function. Depdc5-null
neurons expressing Q542P also were comparable to WT DEPDC5-ex-
pressing cells and flox/WT controls. On the other hand, Depdc5-null
neurons expressing F164del were significantly larger than controls,
showing that this null phenotype was not able to be rescued to normal
size (Fig. 6D–F). Again, due to a predicted low level of function at high
expression, the size of F164del-expressing level IV soma were sig-
nificantly smaller than Depdc5-null neurons.
In summary, these data demonstrate that the recurrent F164del
disease variant cannot fully rescue the clinically-relevant aberrant
mTORC1 activity phenotypes that are generated via a Depdc5 ‘second-
hit’ in vivo. Conversely, variant Q542P, which was not functionally
compromised in vitro, fully rescued the mTORC1 phenotype in vivo.
Thus, compromised regulation mTORC1 signalling appears necessary
and sufficient for manifestation of GATOR1 epilepsy/FCD in vivo.
4. Discussion
Mutations in the GATOR1 genes have been reported to be common
causes of familial focal epilepsy, FCD type II and SUDEP (Baldassari
et al., 2018). Despite previous GATOR1 loss-of-function studies im-
plicating mTORC1 deregulation in the pathology, this long-standing
hypothesis has yet to be confirmed for specific patient variants (Bar-
Peled et al., 2013; Hu et al., 2018; Hughes et al., 2017; Ribierre et al.,
2018). Understanding the functional activity of variants in vitro and in
vivo will aid in diagnosis, predictions of disease outcome and targeted
treatment for GATOR1 patients.
We first used GATOR1 null cell lines to perform in vitro functional
screening analysis of 17 NPRL2, NPRL3 and DEPDC5 variants which
were previously predicted to be pathogenic (Baldassari et al., 2018;
Ricos et al., 2016). Our screening revealed that under starvation con-
ditions, six variants: one missense NPRL2 mutation (L105P), one in-
frame DEPDC5 indel mutation (F164del), one nonsense DEPDC5 mu-
tation (D1556*) and three nonsense NPRL3 mutations (S279F fs*52,
W319P fs*13, S460P fs*20) were unable to repress mTORC1 signalling,
confirming that the mode of pathogenesis for these mutants is dereg-
ulation of the pathway.
Despite the incomplete (~65%) penetrance of DEPDC5 F164del, this
variant also has relatively strong genetic evidence of pathogenicity,
being found in three large families with familial focal epilepsy with
variable foci (FFEVF) (Dibbens et al., 2013). In concordance with our
results, this variant has previously been confirmed to have a significant,
although not complete, inability to regulate mTORC1 activity measured
by phosphorylation of S6K in basal conditions (van Kranenburg et al.,
2015). Although only identified as a de novomutation in a single patient
with epilepsy and pachygyria, the DEPDC5 nonsense variant D1556*
was also found to be loss-of-function (Cen et al., 2017). The only other
two DEPDC5 variants with proven loss-of-function are similar muta-
tions (Q1523* and Q1536*) in the C-terminal domain (CTD) due to
protein degradation, suggesting that the CTD has a role in DEPDC5
protein stability (Shen et al., 2018; van Kranenburg et al., 2015). All
NPRL3 variants found to be loss-of-function were nonsense mutations.
All three had truncated the intermediary (INT) or CTD domains, which
are predicted to be important for binding NPRL2 (Shen et al., 2018),
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Fig. 4. Focal deletion of Depdc5 in developing mouse brain using in utero electroporation results in large, dysmorphic neurons with hyperactive mTORC1
activity. (A) Schematic representation of in vivo DEPDC5 variant functional screening. (B) Immunostaining of electroporated 18.5dpc embryo brain using CRE
antibody (red) shows co-expression with GFP-positive neurons. (C) Schematic representation of alleles- including floxed Depdc5 allele before and after the addition of
Cre- and the resulting transcripts. Green arrows indicate primers used in PCRs in relation to cDNA for PCRs (left). (D) PCR using template cDNA from GFP-positive
(Cre +) and GFP-negative (Cre -) brain cells from 18.5dpc brains electroporated at 14.5dpc showing the deletion of exon 3 in the transcripts (right). (E)
Representative p-S6 immunostaining and GFP expression in P42 flox/null and flox/WT brains electroporated at 14.5dpc (scalebar= 100 μm). Boxes indicate region
selected for higher magnification in (E'), showing a control neuron (top) and a large dysmorphic Depdc5 null neuron (bottom, scale bar= 20 μm). Variability in soma
size and morphology in null neurons is represented. (F) Box and whisker plot of p-S6 expression fold change in cortical GFP-positive neurons in flox/null mice (n=9)
normalised to flox/WT controls (n= 5) (****=p < .0001, two-tailed unpaired t-test). (G) Box and whisker plot of fold change in soma size of cortical flox/null
GFP-positive neurons normalised to flox/WT GFP-positive neurons (n=11, n=7 respectively, ****= p < .0001 two-tailed unpaired t-test). (H) Representative
NeuN immunostaining showing expression in large Depdc5 null neurons. (scale bar= 20 μm). (I) Representative images of increased dendritic branching of GFP-
neurons in flox/null mice compared to flox/WT mice (scalebar= 100 μm). (J) Box and whisker plot of number of dendritic branch points obtained using neuronal
filament tracing and reconstruction in flox/null brains (n=4) and flox/WT brains (n=4, ***= p < .001 two-tailed unpaired t-test). (For interpretation of the
references to colour in this figure legend, the reader is referred to the web version of this article.)
Fig. 5. Depdc5 null neurons mice have migration defects and lower seizure thresholds. (A) Representative cortical images of P42 mice brains electroporated at
14.5pdc show the distribution of GFP-neurons in flox/null and flox/WT brains over cortical layers II-IV marked with CUX1 immunostaining (scale bar= 100 μM).
(B,C) Box and whisker plot of the number of GFP-positive neurons in layer II/III (B) or layer IV (C) of P42 flox/null (n= 9) or flox/WT (n= 4) brains electroporated
at 14.5dpc (****= p < .0001, two-tailed unpaired t-tests). (D) Survival curve of PTZ seizure test shows increased seizure susceptibility in P42 Depdc5 flox/null mice
(n=5) compared to flox/WT mice (n= 7) electroporated at 14.5dpc, (***= p < .001 Mantel-Cox test).
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complex formation. Only one NPRL2 variant was functionally com-
promised (L105P). Although the genetic evidence for L105P disease
causation is limited to a single three generation pedigree, this is
nevertheless one of the most extensive pedigrees available for an NPRL2
variant, which are typically reported in small nuclear families or in
affected individuals harbouring de novo mutations. Furthermore, the
recently solved structure of GATOR1 indicates that L105 is located
within an α-helix which is proximal to an interaction interface between
NPRL2 and DEPDC5. A proline substitution at this position may break
or disrupt this α-helix and impair complex formation and/or affect the
positioning of a nearby critical catalytic arginine residue (R78)
(Richardson, 1981; Shen et al., 2019, 2018).
Interestingly, the majority of GATOR1 variants screened did not
have significantly altered functional ability in the current in vitro assay
despite previous predictions of their pathogenic nature (Carvill et al.,
2015; Dibbens et al., 2013; Ricos et al., 2016). Indeed, of the nine
GATOR1 missense mutations that we tested, only one was functionally
compromised. This finding is consistent with a previous study on
DEPDC5 variants which found nine of 12 (75%) independent missense
variants did not have significantly altered function (van Kranenburg
et al., 2015). Furthermore, a recent prediction analysis has re-classified
many GATOR1 variants of ‘unknown significance' rather than ‘likely
pathogenic’ (Baldassari et al., 2018; van Kranenburg et al., 2015).
Notably however, DEPDC5 H214D, which was classified as likely pa-
thogenic, was found in our assay to function normally. Together, these
findings highlight the importance of functional assessment for diag-
nosing variants as causative of disease, particularly for missense var-
iants. Furthermore, the treatment of patients with these mutations
using mTORC1 inhibitors such as rapamycin should be used with cau-
tion to avoid unnecessary side effects (Tran and Zupanc, 2015).
The GATOR1 null cell starvation rescue assay developed in this
study should be useful in this regard with the following caveats. It is
possible that variants with subtle functional defects or partial loss-of-
function were not captured in our flow-based in vitro assay. Performing
the screen in (disease relevant) neuronal cells may help identify tissue-
specific effects of variants (or eliminate tissue specific compensatory
mechanisms). Ex vivo electroporation and culture of organotypic brain
slices may help identify subtle migration defects. Furthermore, the
assay was conducted under complete nutrient depravation, and selec-
tively evaluating the impact of specific amino acid depletion may in-
crease the sensitivity of identifying pathological variants. Finally, var-
iants were likely expressed above the endogenous levels, which may
reduce the sensitivity of the assay. For example, NPRL2 variant R34*
(which showed slight, but not significantly altered function in our
assay) may have deleterious physiological effects in endogenous con-
ditions. The function retained in our assay may be due to the expression
of the alternate isoform due to an alternate first exon (AFE) that falls
after this mutation, which in our assay may be expressed above en-
dogenous levels. It is also possible that some nonsense mutants found to
be functional in vitro may be loss-of-function in vivo due to nonsense
mediated decay (NMD).
To further our understanding of the pathological mechanism of
DEPDC5 disease variants, we developed a conditional mouse that
modelled a somatic ‘second-hit’ Depdc5 mutation during CNS develop-
ment on a heterozygous background. This unique model exhibited pa-
thogenic features redolent of epilepsy and FCD type II, including hy-
peractive mTORC1 signalling, large dysmorphic soma, increased
dendritic branching, defective migration and lower seizure thresholds.
These data support a ‘second-hit’ mechanism of disease and is con-
sistent with the phenotypes recently described in other Depdc5 rodent
models (Hu et al., 2018; Ribierre et al., 2018; Yuskaitis et al., 2017).
Our approach to modelling the human disease differs from previous
studies in that the mice are germline heterozygotes before introduction
of a second somatic mutation during development. Moreover, by em-
ploying the Cre/loxP system for the ‘somatic hit’, we can ensure that the
somatic mutation causes complete loss-of-function. In contrast, other
approaches utilise the CRISPR/CAS9 system on a WT background,
where the mutational outcomes are variable and underlying global
heterozygosity is not present (Hu et al., 2018; Ribierre et al., 2018).
While the overall phenotype of published Depdc5 focal deletion rodent
models is relatively consistent, the sub-type classification of the FCD
phenotype remains unresolved. Based on our inability to detect im-
mature neuron marker Nestin or SMI32 in Depdc5-null neurons, our
data favours a FCD type IIa classification, which is however not con-
sistent with other models. While no Depdc5-null/Nestin-positive cells
were detected in the rat model reported by Hu et al., this group did
present aberrant cytoplasmic SMI32 expression, similar to findings from
Yuskaitis et al. who showed disorganized SMI311 staining in the
Depdc5-null mouse brain (Yuskaitis et al., 2017). Furthermore, balloon-
like cells were reported in a conditional Depdc5 mouse model by Ri-
bierre et al. based on morphological and histopathological criteria,
which concluded FCD type IIb. These FCD-like cells may become more
apparent with age, as it may be the case that hyperactive mTORC1
activity has accumulative effects, and may explain the inconsistencies
between models. With more patient samples and animal models, the
finer classification of FCD related to GATOR1 genes should become
clearer (Hu et al., 2018; Ribierre et al., 2018; Scerri et al., 2015; Sim
et al., 2016; Weckhuysen et al., 2016).
We used this mouse model to further validate the functional status
of two DEPDC5 variants based on their contrasting activities in the in
vitro null rescue experiments. DEPDC5 variant Q542P, which has been
recently classified as ‘likely pathogenic’ based on allele frequency and
in silico prediction tools, was not functionally compromised in our in
vitro assay (Baldassari et al., 2018). Consistent with the in vitro assay,
expression of Q542P in vivo rescued mTORC1 hyperactivity and cyto-
megalic neurons in Depdc5-null cortices, indicating that this variant
retains at least some function. Additional functional assessment of the
Q542P variant should be performed to further investigate its potential
pathogenesis. In contrast, the co-electroporation of functionally com-
promised F164del DEPDC5 variant was unable to rescue null pheno-
types to WT levels in vivo thereby providing independent confirmation
of its pathogenicity. These in vivo data further validate our DEPDC5 in
vitro functional assay and provide evidence that mTORC1 deregulation
is necessary and sufficient for manifestation of DEPDC5-associated
epilepsies. Testing seizure susceptibility and migration at later time
points with whole-brain expression of DEPDC5 variants would provide
Fig. 6. In vivo functional testing of DEPDC5 variants F164del and Q542P. (A) PCR of Flag sequence using cDNA template from GFP-positive (ipsilateral) and
GFP-negative (contralateral) brain tissue from electroporated mouse brains (P0) showing the presence of the co-electroporated Depdc5 constructs transcripts. (B)
Representative p-S6 immunostaining of GFP-positive cortical neurons of Depdc flox/null P15 mice co-electroporated with WT DEPDC5WT, F164del or Q542P mutant
constructs, and flox/null and flox/WT mice electroporated with Cre/GFP only (scalebar= 100 μm. (C) Box and whisker plot of the fold change in p-S6 expression
shows P15 flox/null mice co-electroporated with WT DEPDC5 (n=6) and Q542P (n=4) have p-S6 levels rescued to control levels (n=10) while flox/null co-
electroporated with F164del (n= 6) is comparable to flox/null mice electroporated with Cre-only (n=6, ****=p < .0001 one-way ANOVA with Tukey's multiple
comparisons tests). (D) Representative images of P15 cortices showing representative sizes of GFP-positive electroporated neuron soma (scalebar= 100 μm). CUX1
immunostaining (red) marks layers II-IV. One representative neuron for both layer II/II and layer IV is selected, for higher magnification (scale bar= 10 μm). (E,F)
Box and whisker plots of fold change in soma size for P15 flox/null co-electroporated with WT, F164del or Q542P Depdc5 constructs (n= 7, n=9, n= 4 re-
spectively) as well as flox/null and flox/WT Cre-only electroporated (n= 7, n= 9 respectively) control brains for layer II/III cortical GFP neurons, (E) and layer IV
cortical GFP neurons (F) (****=p < .0001, one-way ANOVA with Tukey's multiple comparisons tests). (For interpretation of the references to colour in this figure
legend, the reader is referred to the web version of this article.)
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further insight into variants that appear to have no functional impair-
ment in our assays. Indeed, these variants require more investigation
into their pathogenic ability, which may reveal the role of other un-
discovered alternative pathogenic mechanisms. Given the functional
interaction of DEPDC5 with NPRL2 and NPRL3, the validation of
DEPDC5 variant assay results in vivo indicates that the results of NPRL2
and NPRL3 in vitro functional testing is likely reflective of their in vivo
functional status. Thus, the in vitro assay and the in vivo mouse model
rescue approach provide useful screening platforms for existing and
emerging variants to contribute to a better understanding of function-
ally important regions and residues, allowing further refinement of
classifications of disease causing variants.
While other models of hyperactive mTORC1 in the brain have also
resulted in similar cortical malformation phenotypes, the specific me-
chanism by which mTORC1 hyperactivity causes epilepsy remain elu-
sive (D'Gama et al., 2015; Goto et al., 2011; Park et al., 2018; Yuskaitis
et al., 2017). The misplacement of neurons, abnormal size and mor-
phology, and increased dendrite growth might lead to disrupted or
inappropriate synaptic connections, which could manifest as seizures.
However, previous investigations have shown that not all these archi-
tectural features may be necessary for causing seizures, suggesting that
changes in other intrinsic electrogenic processes regulated by mTORC1
could lead to hyper-excitable neurons (Baulac, 2016; Hsieh et al., 2016;
Magri et al., 2011). Therefore, while mTORC1 hyperactivity is an es-
tablished molecular mechanism behind GATOR1 epilepsy and FCD,
more investigation is required into which downstream effects lead to
seizures. Additionally, further investigation into the possibility that
mutations that affect mTORC1 regulation, whether in the same or dif-
ferent genes, may have an additive effect contributing to aberrant
mTORC1 activity over a certain tolerable threshold and cause disease.
Thus, it may be prudent to broaden the search for somatic mutations to
include mTORC1 pathway genes that are not germline heterozygous
(e.g. NPRL2 or NPRL3 in an affected DEPDC5 germline heterozygous
individual) and perform function assessment of candidate variants
using the approach described herein (D'Gama et al., 2015; Park et al.,
2018).
In conclusion, we employed in vitro and in vivo methods to func-
tionally analyse GATOR1 variants and confirmed missense, in-frame
deletion and nonsense variants in NPRL2, NPRL3 and DEPDC5 to be
pathogenic. This data also provides the first in vivo evidence that
DEPDC5 variants have impaired functional ability to regulate mTORC1
signalling, and are therefore pathogenic. Additionally, our data sup-
ports that GATOR1 mutations may cause focal epilepsy and FCD
through a second somatic hit mechanism. Finally, we demonstrate that
many putative disease-causing variants retain function, highlighting the
importance of functional screening in classification and diagnosis of
disease variants.
5. Materials and methods
5.1. Patient mutations
NPRL2, NPRL3 and DEPDC5 variants were selected based on avail-
able literature with an emphasis on functional assessment of missense
or in-frame mutations (Carvill et al., 2015; Cen et al., 2017; Dibbens
et al., 2013; Ricos et al., 2016).
5.2. Cell culture
HEK293T cells were cultured in DMEM (GIBCO #12430062) with
10% FCS and 1% Glutamax incubated in 5% CO2 at 37 °C. Starved
conditions are in Earle's Balances Salt Solution (EBSS) for 1 h (GIBCO
#14155063). Rapamycin 20 nM was added to EBSS for the rescue
condition.
5.3. Generating GATOR1 null clones
Null lines for each of the GATOR1 genes were generated by co-
transfecting cells with two CRISPR/CAS9 plasmids: pX458 (Addgene
#48139) and pX459 (Addgene #62988), containing sgRNAs targeting
regions flanking an exon for deletion leading to an early frameshift
(Supplemental Fig. 1A). 24 h after transfection, cells underwent pur-
omycin selection (2 μg/μL for 48 h). To select for PX458 plasmid
transfection, only GFP-positive cells were grown. Cells were expanded
to clonal cell lines and screened for exon deletion through PCR, or
absence of protein by western blot (Supplemental Fig. 1B,C). For each
of the three GATOR1 genes, two independent null cell lines were chosen
for further experimentation in the mutation screening assay.
5.4. PCR based genotyping of null cell clones
DNA extraction from cells was performed with High Pure PCR
Template purification Kit (Roche). Selection of null clone candidates
was based on a PCR which amplified the region flanking the targeted
exon and selected on size of predicted deletion. A secondary PCR was
performed to confirm the exon deletion using primers within the exon
sequence. PCR products were purified with QIAgen PCR Purification kit
(CAT #28106) kit and Sanger sequenced performed by AGRF verified
exon deletion.
5.5. Protein extraction and Western blots
Cell lysates were extracted using extraction buffer (150mM NaCl,
1% NP-40, 0.5% deoxycholate, 0.1%SDS, 50mM Tris-HCl pH 7.5) with
protease inhibitor (Roche #4693159001) and phospho-stop tablets
(Roche #4906845001), incubated at 4 °C for 30min. Lysates were run
on Invitrogen Bolt precast 4–12% polyacrylamide gels and transferred
to PVDF membrane before blotting. Antibodies and their corresponding
dilutions were: rabbit anti-NPRL3 1/500 (Sigma #HPA011741), mouse
anti-NPRL2 1/1000 (Santa Cruz #sc-376986), mouse anti-Flag 1/1000
(Sigma #F3165), goat anti-GFP 1/5000 (Abcam ab5450).
5.6. Variant expression constructs
Flag-Nprl2 (#46333), Flag-Depdc5 pRK5 (#46340) and HA-Nprl3
(#46330) were purchased from Addgene. Variant constructs were
generated with site-directed mutagenesis of these constructs using the
QuikChange Lightning Site-Directed Mutagenesis kit (Agilent
#210518). For DEPDC5 variant S1104 L, exon 33 was cloned into Flag-
Depdc5 pRK5 before mutagenesis.
5.7. Flow Cytometry
Flow cytometry analysis was performed 24 h after transfection and
immediately after 1 h starvation. Cells were fixed with Cytofix™ (BD
#554655), permeabilised in Phosflow™ Perm Buffer III (BD #558050)
and stained for 1 h with primary antibody diluted in incubation buffer
(PBS/0.5% bovine serum albumin) and 30min with secondary anti-
body. Antibodies were: rabbit anti-phospho-S6 Ribosomal Protein
(Ser240/244) (Cell Signalling, #5364, 1/100 [1 μg/μL]), Normal
Rabbit IgG (Cell Signaling #3900, 1/1000 [1 μg/μL]), Alexa Fluor 647
(AbCam #ab150075, 1/2000). A minimum of 10,000 events were
analysed for each sample with a BD Acuri™ C6. Analysis was performed
with FlowJo software. Y-axis gating was based on P-S6 staining in
complete media conditions, representing a threshold of high mTORC1
activity. X-axis gating was based on untransfected control cells.
5.8. Immunohistochemistry
Immediately after 1 h serum starvation, cells were fixed in 4% PFA/
PBS for 15min RT. Blocking in PBS/0.1% Triton X-100/10% horse
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serum was performed for 30min, followed by overnight incubation at
4 °C with primary antibody diluted in blocking solution. Cells were
washed before a 2–4 h RT incubation with diluted secondary antibody.
Slides were mounted in Prolong™ Gold Antifade with DAPI (Invitrogen
#P36931).
For mouse brain immunofluorescence, P15 and P42 mice were eu-
thanized with Lethabarb Euthanasia Injection and subject to cardiac
perfusion with 4% PFA/PBS. Brains were dissected and fixed in 4% PFA
overnight (a further 16 h) at 4 °C then cryoprotected in 30% sucrose
overnight at 4 °C, and embedded in frozen OCT medium. 16 μm sections
were cut from frozen tissue using Leica CM1900 cryostat. Tissue was
blocked and stained as described above. Antibodies and their corre-
sponding dilutions were: rabbit anti phospho-S6 Ribosomal Protein
(Ser240/244) (Cell Signaling, #5364, 1:1000), mouse anti-NeuN 1/100
(Millipore, #MAB377), rabbit anti-Cre 1/400 (AbCam ab24607),
mouse anti-Flag 1/1000 (Sigma #F3165), rabbit anti-Cux 1/400 (Santa
Cruz #sc13024), chicken anti-GFP 1/1000 (Abcam ab13970).
All imaging was performed with a Nikon Eclipse Ti microscope and
Nikon Digital Sight DS-Qi1 camera.
5.9. Animal housing and breeding
Experiments were performed on mice housed in IVC cages with a
previously published null allele (Hughes et al., 2017) and a newly
generated floxed allele generated with CRISPR/CAS9 (see below).
These alleles were propagated in two separate colonies which were bred
together using a flox/flox x null/WT cross to generate flox/null and
flox/WT offspring for electroporation. Depdc5 flox and null mice were
generated and maintained on a C57BL/6J genetic background.
5.10. Generation of Depdc5 floxed mice
A pair of sgRNAs (5′-GATAGGGATACTGGTCTTCTAGG-3′, 5′-CTG
ATCTCAAAAACTACTTCAGG-3′) were designed to flank exon 3 of
Depdc5 (mm9) and cloned into PX330. T7 PCR and IVT performed to
generate sgRNA (Wang et al., 2013). Single stranded oligo donor se-
quences were designed containing loxP sequences (and restriction sites
EcoR1 and Nhe1) with 40 bp of homology either side, corresponding to
either side of the targeted cut site.
C57BL/6J mouse zygotes were injected with both sgRNAs, oligo
donors and spCas9 RNA in injection buffer and transferred to pseudo-
pregnant females as previously described (Robertson et al., 2018). One
founder mouse from these injections had a correctly targeted allele with
both loxP sites inserted, which was confirmed first by separate PCRs
and Sanger sequencing around the targeted regions. The loxP insertions
were subsequently confirmed to be in cis after cloning of the PCR
product spanning both sites into pGEMTeasy (#A1360) and sequencing
from plasmid. The founder was crossed to C57BL/6J mice to generate
F1 progeny carrying the floxed allele. F1 progeny were used to establish
the flox colony.
5.11. Mouse genotyping
KAPA Express Extract Kit (Sigma KK7100) was used to purify
genomic DNA from tail tips. For genotyping, the Depdc5 floxed allele
was identified based on by size after PCR amplifying around the region
of loxP insertion. The following primers were used: 5’ loxP site:
5′-CATGCCTACCTACCTTGAATTTTT-3′, 5′-TCACAGGCACAAGCCAC
TAC-3′; 3′ loxP site: 5′- AGAGCTTCAGCCCAACTCTG-3′, 5′- CTGCACT
CACATGCACAGG-3′ (annealing temperature 60°, Epicentre FailSafe
2× PreMix Buffer D). The Depdc5 null allele was identified with a PCR
using primers 5′-CATGCCTACCTACCTTGAATTTTT-3′, 5′-AACAGCCA
GTGCTCTTACCAG-3′ (annealing temperature 62°, KAPA Taq Buffer A),
which produces an amplicon around 500 bp indicating the 2 kb which
includes exon 3. This PCR does not amplify the WT allele due to a short
extension time. To identify the WT Depdc5 allele, an internal PCR
amplifying within the 2 kb region that is deleted in the null allele was
used with primers 5′- GGCTGATCCGTGTGGAGTAT-3′, 5′- AGGGCCAC
AACAGTAAATGG -3′ (annealing temperature 60°, Epicentre FailSafe
2× PreMix Buffer D).
6. In utero electroporation and plasmid preparation
In utero electroporation was performed on 14.5dpc embryos from
pregnant time-mated females (from a flox/flox× null/WT cross) as
previously described (Okada et al., 2007). Plasmids were purified with
QIAgen endo-free Maxi kit (#12362) and concentrations were: pCAG-
GFP plasmid, 1 μg/μL (Addgene #11150), pCIG-Cre, 1.5 μg/μL, Flag-
DEPDC pRK5 3 μg/μL (Addgene #46340), Flag-Depdc5-F164del pRK5,
3 μg/μL, Flag-Depdc5-Q542P pRK5, 3 μg/μL. pCIG-Cre plasmid was a
gift from Dr. Julian Heng. DEPDC5 constructs were generated as de-
scribed above and used equimolar to pCIG-Cre. pCAG-GFP plasmid was
used at a lower concentration to decrease the likelihood of electro-
poration of only pCAG-GFP. 0.1% Fast Green was added to mix and 1-
2 μL was injected into one lateral ventricle using a mouth pipette and
pulled capillary needle (Harvard Apparatus #GC100TF-10).
7. DEPDC5 transcript detection in vivo
GFP-positive 18.5dpc brain tissue was microdissected and trypsi-
nised for 20 mins at 37 °C then aspirated with a Pasteur pipette to
dissociate. BD FACSAria™ Fusion was used to sort the GFP-positive
cells. RNA was extracted from sorted GFP-positive cells with TRIzol/
chloroform protocol and purified with QIAgen RNeasy Mini Kit (ID
#74104). cDNA was made from extracted RNA with Applied
Biosciences High-Capacity cDNA RT Kit (#4368813). RT-PCR was
performed on GFP positive and GFP negative cDNA to amplify the re-
gion surrounding the targeted exon to detect the deletion of the exon
based on size using primers: 5′-GCAAGATGACTTCCCTGCTC-3′,
5′-CCACCAGGTCAAGAGTCACA-3′. RNA was extracted from P0 mice
electroporated with DEPDC5 constructs to perform RT-PCR using pri-
mers amplifying the N-terminal FLAG and DEPDC5 sequence to confirm
successful electroporation.
7.1. PTZ seizure test
85mg/kg pentylenetetrazole (PTZ) was subcutaneously injected
into P42 flox/WT (n=7) and flox/null (n=5) mice which were ob-
served individually in clear cages for drug-induced seizure phenotypes
culminating in tonic-clonic seizure. Time taken to generalised tonic-
clonic (GTC) seizure was measured. Mice not reaching GTC seizure in
1 h were humanely euthanised.
7.2. Dendrite branching analysis
Confocal microscopy images of electroporated cortices were taken
at 20× using (Olympus FV3000). Confocal images were analysed in
IMARIS software (Bitplane) to perform filament tracing of GFP-neurons
to predict/reconstruct dendritic structure. The z-series was recon-
stituted into a 3D image with IMARIS software and dendritic branch
points were detected with Filament tracer software as previously de-
scribed (Kaneko et al., 2011) and measured for (27–63) neurons per
mouse (neurons present in field of view) for flox/null (n=4) and flox/
WT (n=4). Fluorescence threshold parameters of dendrite detection
was manually set above background.
7.3. Immunofluorescence analysis and statistical analysis
For in vitro functional assays, Two-Way Anovas with Dunnett's
multiple comparisons tests against WT NPRL2, NPRL3 or DEPDC5 were
performed (n=5–7).
Immunofluorescence analysis was performed with Nikon NIS-
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Elements software. For p-S6 240/244 analysis, mean fluorescence in-
tensity was measured for 10 GFP-positive neurons randomly chosen on
the DAPI channel, blinded to genotype (n=7 flox/WT, n=11 flox/
null mice). Background non-stained levels of intensity was subtracted.
Values were normalised to flox/WT control and Two tailed unpaired t-
test was performed for P42 brains (flox/WT n=5, flox/null n=9).
One-Way Anova with Tukey's multiple comparisons performed for P15
samples (flox/WT n=9, flox/null n= 7, DEPDC WT n=7, F164del
n=9, Q542P n=4).
Soma size measurement was performed on 10–20 cells per mouse
using freehand area tool on NIS-Elements software for flox/WT mice
(n=7) and flox/null (n= 11) P42 mice by drawing around the soma
on the GFP channel. At P15, CUX1 and DAPI staining was used to
distinguish layer II-III from layer IV based on cell density, and at least
10 GFP-positive soma from layer II-III or layer IV were measured per
mouse for flox/WT mice (n=9), flox/null (n= 7), F164del (n= 9)
and Q542P (n= 4) were measured and analysed with one-way ANOVA
with Tukey's multiple comparisons tests.
CUX1 and DAPI staining were used to define boundaries of layers II/
III and IV of the cortex based on cell density and the location of GFP-
positive neurons at P42 for n= 4 flox/WT mice and n=6 flox/null
were measured. The total number of cells per field of view at 10×
magnification were counted and a proportion of cells in layers II/III was
calculated. (Two-tailed unpaired t-test).
For dendritic branching analysis, 27–63 neurons per animal were
subject to dendritic filament tracing, and number of dendritic branch
points per neuron measured. Two-tailed unpaired t-test was used to
compare number of dendritic branch points in flox/null (n= 4) and
flox/WT (n= 4) mice.
PTZ survival curves for n=7 flox/WT mice and n= 5 flox/null
mice were compared with Mantel-Cox test.
All statistical analysis was performed on GraphPad Prism 7. Box and
whisker plots show minimum and maximum range (whiskers) and are
divided into two boxes and two whiskers, each representing 25% of the
data. The middle bar represents median value.
7.4. Study approval
All animal work was conducted in accordance with Australian
guidelines for the care and use of laboratory animals following approval
by The University of Adelaide Animal Ethics committee and SAHMRI
ethics committee (approval numbers S-2014-169, S-2015-200 and
SAM254).
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